22,625 Shares in Rockwell Medical, Inc. (NASDAQ:RMTI) Acquired by Barclays PLC

Barclays PLC purchased a new position in shares of Rockwell Medical, Inc. (NASDAQ:RMTI) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,625 shares of the company’s stock, valued at approximately $90,000. Barclays PLC owned about 0.07% of Rockwell Medical as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of RMTI. Armistice Capital LLC grew its stake in Rockwell Medical by 22.5% during the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock worth $5,670,000 after buying an additional 592,000 shares during the period. HighTower Advisors LLC grew its stake in Rockwell Medical by 75.6% during the third quarter. HighTower Advisors LLC now owns 57,413 shares of the company’s stock worth $228,000 after buying an additional 24,715 shares during the period. State Street Corp grew its stake in Rockwell Medical by 21.5% during the third quarter. State Street Corp now owns 95,004 shares of the company’s stock worth $377,000 after buying an additional 16,800 shares during the period. Jane Street Group LLC purchased a new stake in Rockwell Medical during the third quarter worth approximately $534,000. Finally, XTX Topco Ltd grew its stake in Rockwell Medical by 45.7% during the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after buying an additional 8,922 shares during the period. Institutional investors and hedge funds own 23.31% of the company’s stock.

Rockwell Medical Price Performance

Shares of RMTI stock opened at $2.13 on Thursday. The company has a market capitalization of $68.84 million, a PE ratio of -42.60 and a beta of 1.38. The firm has a fifty day simple moving average of $2.55 and a 200-day simple moving average of $2.73. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. Rockwell Medical, Inc. has a twelve month low of $1.16 and a twelve month high of $5.15.

Wall Street Analyst Weigh In

Several research firms have issued reports on RMTI. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Rockwell Medical in a research note on Monday, December 23rd. RODMAN&RENSHAW upgraded shares of Rockwell Medical to a “strong-buy” rating in a research note on Thursday, November 14th. Rodman & Renshaw initiated coverage on shares of Rockwell Medical in a research note on Thursday, November 14th. They set a “buy” rating and a $5.00 price objective for the company. Finally, StockNews.com downgraded shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research note on Friday, December 20th.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.